BioCentury
ARTICLE | Company News

Moderna Therapeutics, Merck deal

January 18, 2016 8:00 AM UTC

Moderna and Merck amended a 2015 deal to include rights to develop and commercialize an additional vaccine program, including mRNA 1566, and a set of related, undisclosed vaccine candidates against a fifth undisclosed target. The original deal granted Merck rights to five mRNA-based treatments and vaccines against four undisclosed viruses. ...